News room
TechnoPhage announces signing of a PRR Grant Agreement with the Portuguese Government
Technophage, together with partners LX Bio, VectorB2B and FFUL is pleased to announce the signing of a new PRR Grant Agreement with the Portuguese...
TechnoPhage Announces First Clinical Safety Results with Innovative Biological Product TP-102
TechnoPhage is proud to announce that the first part of the Phase I/IIa Clinical Trial with TP-102 (REVERSE study) has been completed. The study...
Technophage Annual Meeting 2021
Last week TechnoPhage held its Annual Meeting where the CEO, Miguel Garcia, took the opportunity to speak to the collaborators about recent...
TechnoPhage Announces Identification of a New Antibody with Therapeutic Potential for COVID-19
We are proud to announce that a potential new therapeutic antibody for the treatment of COVID-19 has been identified. The candidate antibody was...
Technophage creates LX Bio: a new company to ensure the industrialization of biologics
Technophage’s plans for the next few years have been revealed in a brand new article in Portuguese Weekly Journal “Expresso”. The biopharma is...